Cassava Sciences to Present at H.C. Wainwright’s 23rd Annual Global Investment Conference

Rhea-AI Summary

Cassava Sciences (Nasdaq: SAVA), a biotechnology company dedicated to Alzheimer’s treatment, will present at the H.C. Wainwright’s 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will feature a fireside chat led by Vernon T. Bernardino, PhD, Managing Director of Biotechnology Equity Research.

The event starts on September 13 at 7:00 a.m. Eastern Time, and the chat will be available for replay on the company’s website for 90 days.

AUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will present at H.C. Wainwright’s 23^rd Annual Global Investment Conference, a virtual event that takes place September 13-15, 2021.

Cassava Sciences’ presentation is a ‘fireside chat’ with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright.

Event details follow:
Date:	Monday, September 13th
Time:	7:00 a.m. Eastern Time
Webcast:	https://www.CassavaSciences.com/company-presentations

Cassava Sciences’ fireside chat will be available for replay for 90 days following the conference on www.CassavaSciences.com in the ‘Investors’ section.

About Alzheimer’s Disease
Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to over 150 million by 2050.¹ The annual global cost of dementia is now above $1 trillion, according to Alzheimer’s Disease International, a charitable organization.

About Cassava Sciences, Inc.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease.

Simufilam and SavaDx were both developed in-house. Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer’s disease, and related technologies, without royalty obligations to any third party.

For more information, please visit https://www.CassavaSciences.com

Contact Information:
Eric Schoen, Chief Financial Officer
Cassava Sciences, Inc.
eschoen@CassavaSciences.com
(512) 501-2450

¹ Alzheimer's Disease International, Dementia Statistics, available on-line and accessed September 8, 2021.

 

FAQ

What is the date of Cassava Sciences' presentation at the H.C. Wainwright conference?

Cassava Sciences will present at the H.C. Wainwright conference on September 13, 2021.

What time is Cassava Sciences' fireside chat scheduled?

The fireside chat will start at 7:00 a.m. Eastern Time.

Where can I watch the Cassava Sciences presentation?

You can watch the presentation on Cassava Sciences’ website at https://www.CassavaSciences.com/company-presentations.

How long will the Cassava Sciences presentation be available for replay?

The presentation will be available for replay for 90 days after the conference.

What is the focus of Cassava Sciences as a company?

Cassava Sciences focuses on discovering and developing innovations for chronic neurodegenerative conditions, particularly Alzheimer’s disease.